The recent notable events of Sanofi include several key developments, various collaborations, and continued expansion in the biopharmaceutical industry. Among the highlights, it completed a marketing authorisation transfer for Nuvaxovid from Novavax which earned Sanofi a $25 Million Milestone Payment. It's also reported that Dupixent, a flagship product of Sanofi, has brought strong earnings offsetting a shortfall in vaccine sales and nearing a remarkable $5 billion in sales. An increased valuation is anticipated from new drug pipelines, of which Regeneron’s Dupixent met all endpoints. Sanofi also entered into a $500 million deal with Evoq to obtain next-generation autoimmune technology and debuted two cardiovascular drugs in China to deepen its partnership there. However, the company's vaccine for RSV in toddlers failed in phase 3, leading to the decision to drop the project. Also, there was a disappointing trial result for an eczema drug. Despite these setbacks, Sanofi gets noticed for its huge commitments like the significant $20 billion investment to US manufacturing through 2030. In addition, Sanofi has efficiently used Digital Transformation and AI across its operations including R&D, production, and supply chain.
Sanofi News Analytics from Thu, 03 Apr 2025 20:10:10 GMT to Fri, 07 Nov 2025 20:59:45 GMT - Rating 7 - Innovation 6 - Information 8 - Rumor 5
